Charles Dockendorff, CFO of Covidien Plc., tells investors that the impending medical device tax will affect about half of the company's total sales.
Covidien plc (NYSE:COV) officials aren't predicting any doomsday scenarios for the incoming medical device tax.
In a conference call with investors Thursday, company CFO Charles Dockendorff called the tax "just another business issue" the company would manage as it moves forward.
A quartet of California cardiologists filed suit against a county hospital, claiming that they were persecuted and forced out of their jobs after exposing inadequate patient care.
Drs. Singh and Ihnken
A group of California cardiologists filed a lawsuit against Santa Clara Valley Medical Center, alleging that they were harassed out of their jobs after they complained about a pattern of compromised patient safety at the hospital.
The plaintiffs are led by echocardiographer Dr. Geeta Singh and cardiothoracic surgeon Dr. Kai Ihnken, with 2 additional cardiologists named alongside them in the lawsuit.
Covidien shares jump on Wall Street after it raises its outlook for 2012 and posts a Street-beating quarter of record-breaking adjusted gross margins.
Covidien plc (NYSE:COV) was in Wall Street's good graces this morning after beating expectations and boosting its 2012 fiscal guidance.
The Mansfield, Mass.-based company touted record adjusted gross margins of 58.8% for the 3 months ended Dec. 24, 2011, 1.2 points higher than during the same period in 2010.
Covidien also upped its 2012 fiscal guidance, forecasting 3% to 5% sales growth. Its previous guidance was about a point lower.
St. Jude responds to a summit on the recall of its Riata defibrillator leads, Boston Scientific fights the hype on deformation concerns on its thinner stents and Covidien announces a new head for its $1.4 billion global vascular therapies business.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Group purchasing organization Premier and Child Health Corp. ink a slew of new supply deals for medical device products.
Group purchasing organization Premier said it signed a raft of supply deals for a variety of medical device products.
The Charlotte-based GPO said it signed deals for endomechanical, trocar, suture and topical skin adhesives with 16 companies.
, Clear Advantage Collar
, ConMed Corp.
, DeRoyal Industries
, Edwards Lifesciences
, Ethicon Inc.
, Medline Industries Inc.
, Microline Surgical
, Premier Healthcare Alliance
, SkinStitch Corp.
, Sorin Group
, Stryker Corp.
, Surge Cardiovascular
, Surgical Innovations US
, Terumo Corp.
, 3M Corp.
, Aesculap Implant Systems LLC
, Applied Medical Resources Corp.
Covidien taps Stacy Enxing Seng, a former executive from its ev3 acquisition, to lead its vascular therapies business; also, Aethlon Medical sets up advisory board; AtriCure hires Lux to be COO; and Sirona Dental loses 2 board members.
Covidien (NYSE:COV) named Stacy Enxing Seng president of its $1.4 billion global vascular therapies business.
Enxing Seng, 47, will lead the division's 4,000 employees, reporting to Peter Wehrly, president of the Mansfield, Mass.-based firm's respiratory & monitoring solutions and vascular therapies division. She joined Covidien in July 2010 after the company spent $2.6 billion acquiring ev3 and its Pipeline embolization treatment for cerebral aneurysms.
Deaths spur Covidien recall, J&J warned on insulin pumps, Depuy shuts down custom devices, CEOs claim emerging markets, thought-leaders huddle on Riata, more J&J execs deposed and Stryker settles for $15M this week.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.